PharmaTimes October 15, 2024
John Pinching

Partnership to harness AI for DUB-focused preclinical programmes

Dundee-based Ubiquigent Limited and San Francisco’s Alleo Labs Corp have entered a strategic partnership to advance deubiquitinase (DUB)-focused drug discovery using AI.

The collaboration aims to combine Alleo’s AI-based platform with Ubiquigent’s expertise to speed up preclinical programmes targeting neurological diseases.

Under this partnership, Ubiquigent will gain exclusive access to Alleo’s AI software, RubDUB, to find novel DUB-modulating compounds.

These compounds are crucial for developing DUB inhibitors, DUB-targeting PROTACs, and DUB-Targeting Chimeras (DUBTACs). Meanwhile, Alleo will leverage Ubiquigent’s platforms to boost its in-house precision neuroscience programmes.

Jason Mundin, CEO of Ubiquigent, highlighted the potential of this collaboration: “The potential for the development of novel DUB-targeting therapeutics has never been greater, and this...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Biotechnology, Partnerships, Pharma, Pharma / Biotech, Technology, Trends
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article